These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23530732)

  • 1. Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.
    Mamdani F; Berlim MT; Beaulieu MM; Turecki G
    World J Biol Psychiatry; 2014 Feb; 15(2):135-44. PubMed ID: 23530732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression biomarkers of response to citalopram treatment in major depressive disorder.
    Mamdani F; Berlim MT; Beaulieu MM; Labbe A; Merette C; Turecki G
    Transl Psychiatry; 2011 Jun; 1(6):e13. PubMed ID: 22832429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response.
    Tsai SJ; Hong CJ; Liou YJ; Yu YW; Chen TJ
    Pharmacogenet Genomics; 2008 Oct; 18(10):869-75. PubMed ID: 18794724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.
    Guilloux JP; Bassi S; Ding Y; Walsh C; Turecki G; Tseng G; Cyranowski JM; Sibille E
    Neuropsychopharmacology; 2015 Feb; 40(3):701-10. PubMed ID: 25176167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
    Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
    Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison.
    Matreja PS; Badyal DK; Khosla P; Deswal RS
    Hum Psychopharmacol; 2007 Oct; 22(7):477-82. PubMed ID: 17647298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Patient-reported Outcomes of Quality of Life and Functioning Before and After Treatment of Major Depressive Disorder Comorbid With Alcohol Use Disorders.
    Danovitch I; Steiner AJ; Kazdan A; Goldenberg M; Haglund M; Mirocha J; Collison K; Vanle B; Dang J; IsHak WW
    J Addict Med; 2017; 11(1):47-54. PubMed ID: 27763941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression.
    Tatham EL; Hall GB; Clark D; Foster J; Ramasubbu R
    Eur Arch Psychiatry Clin Neurosci; 2017 Mar; 267(2):135-147. PubMed ID: 27277475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
    Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
    J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
    Gupta M; Neavin D; Liu D; Biernacka J; Hall-Flavin D; Bobo WV; Frye MA; Skime M; Jenkins GD; Batzler A; Kalari K; Matson W; Bhasin SS; Zhu H; Mushiroda T; Nakamura Y; Kubo M; Wang L; Kaddurah-Daouk R; Weinshilboum RM
    Mol Psychiatry; 2016 Dec; 21(12):1717-1725. PubMed ID: 26903268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment factor structures of the Montgomery and Åsberg Depression Rating scale as predictors of response to escitalopram in Indian patients with non-psychotic major depressive disorder.
    Basu A; Chadda R; Sood M; Rizwan SA
    Asian J Psychiatr; 2017 Aug; 28():154-159. PubMed ID: 28784374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prothrombotic platelet phenotype in major depression: downregulation by antidepressant treatment.
    Lopez-Vilchez I; Serra-Millas M; Navarro V; Rosa Hernandez M; Villalta J; Diaz-Ricart M; Gasto C; Escolar G; Galan AM
    J Affect Disord; 2014 Apr; 159():39-45. PubMed ID: 24679387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.
    Bobo WV; Angleró GC; Jenkins G; Hall-Flavin DK; Weinshilboum R; Biernacka JM
    Hum Psychopharmacol; 2016 May; 31(3):185-92. PubMed ID: 26999588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial.
    Hoobehfekr S; Moghaddam HS; Shalbafan M; Hashemi MG; Pirmoradi MM; Sakenian A; Poopak A; Kashefinejad S; Yarahmadi M; Akhondzadeh S
    Psychiatry Clin Neurosci; 2021 Feb; 75(2):57-62. PubMed ID: 33247483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression.
    Shoaib M; Giacopuzzi E; Pain O; Fabbri C; Magri C; Minelli A; Lewis CM; Gennarelli M
    Pharmacogenomics J; 2021 Feb; 21(1):85-93. PubMed ID: 32943772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
    Fabbri C; Crisafulli C; Calati R; Albani D; Forloni G; Calabrò M; Martines R; Kasper S; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):723-735. PubMed ID: 28260126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study.
    Mrazek DA; Biernacka JM; McAlpine DE; Benitez J; Karpyak VM; Williams MD; Hall-Flavin DK; Netzel PJ; Passov V; Rohland BM; Shinozaki G; Hoberg AA; Snyder KA; Drews MS; Skime MK; Sagen JA; Schaid DJ; Weinshilboum R; Katzelnick DJ
    J Clin Psychopharmacol; 2014 Jun; 34(3):313-7. PubMed ID: 24743713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resting-state brain alteration after a single dose of SSRI administration predicts 8-week remission of patients with major depressive disorder.
    Cheng Y; Xu J; Arnone D; Nie B; Yu H; Jiang H; Bai Y; Luo C; Campbell RA; Shan B; Xu L; Xu X
    Psychol Med; 2017 Feb; 47(3):438-450. PubMed ID: 27697079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study.
    Leuchter AF; Cook IA; Marangell LB; Gilmer WS; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; McCracken JT; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):124-31. PubMed ID: 19712979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.